Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).
The Fifth Eilat Conference on New Antiepileptic Drugs (AEDs) took place at the Dan Hotel, Eilat, Israel, 25-29 June 2000. Basic scientists, clinical pharmacologists and neurologists from 20 countries attended the conference, whose main themes included recognition of unexpected adverse effects, new indications of AEDs, and patient-tailored AED therapy. According to tradition, the central part of the conference was devoted to a review of AEDs in development, as well to updates on AEDs that have been marketed in recent years. This article summarizes the information presented on drugs in preclinical and clinical development, including AWD 131-138, DP-valproate, harkoseride, LY300164, NPS 1776, NW 1015, pregabalin, remacemide, retigabine, rufinamide and valrocemide. The potential value of an innovative strategy, porcine embryonic GABAergic cell transplants, is also discussed. Finally, updates on felbamate, fosphenytoin, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide, and the antiepileptic vagal stimulator device are presented.
Bialer
M
M
School of Pharmacy and David R. Bloom Centre for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, Israel. bialer@md2.huji.ac.il
Johannessen
S I
SI
Kupferberg
H J
HJ
Levy
R H
RH
Loiseau
P
P
Perucca
E
E
D000818:Animals; D000927:Anticonvulsants; D002986:Clinical Trials as Topic; D006801:Humans; D009462:Neurology / Q000639:trends*; D013678:Technology, Pharmaceutical
D000927:Anticonvulsants